- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02402140
Influence of Pharmaceutical Care on the Intraindividual Variability of Tacrolimus Concentrations (PharmCare)
A Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intraindividual Variability of Tacrolimus Concentrations Early After Kidney Transplant.
Primary end-point
The primary end-point was the influence of pharmaceutical intervention in tacrolimus intra-subject variability during the first 3 months after kidney transplant. Coefficients of variation were calculated from the average of dose-corrected tacrolimus blood concentration(CV= Standard Deviation (SD) x 100/mean) of study visits day 10, 14, 21, 30, 60 and 90 post kidney transplant.
Secondary end-points
- Secondary outcomes included evaluate percentage of patients who achieved target levels of tacrolimus in day study visits 7, 10, 14, 21, 28, 60 e 90 days after kidney transplant;
- Tacrolimus bioavailability profile during the period of 3 months,characterized by mean and standard deviation (SD) of dose corrected tacrolimus blood concentration(ng/ml/mg);
- Assess patient adherence through validated questionnaire "Portuguese version of Basel Scale Adherence Rating Immunosuppressive Drugs (BAASIS) scale". It consists of a four-item questionnaire measuring nonadherence to immunosuppressives over the past four weeks. This questionnaire assesses omission of single doses or successive doses, timing deviations >2h and dose reductions. Responses are given on a six-point scale: never, once per month, every second week, every week, more than once per week and every day. Patients that answer different from "never" in any of the four questions are considered as nonadherent;
- We evaluated renal function eGFR by Modification of Diet in Renal Disease (MDRD);
- We evaluated Incidence of Infections;
- We evaluated Treated acute rejection episodes;
- We evaluated Death cases;
- We evaluated Graft loss cases;
- We evaluated Discontinuation of immunosuppressive treatment;
- We evaluated Hospital readmissions.
Study Design
This was a single-center, prospective, randomized and controlled study to evaluate the influence of pharmaceutical intervention in tacrolimus intra-subject variability during the first 3 months after transplantation. The authors designed the protocol, acquired and maintained the data, and conducted the statistical analysis. The protocol was approved by an independent ethics committee. All subjects signed a written informed consent before enrollment and the study was conducted according to good clinical practices and declaration of Helsinki. This study was conducted at Hospital do Rim between February 2014 and December 2014, 128 randomized and were followed for 3 months after transplantation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Population
Inclusion criteria were patients who underwent renal transplantation aged ≥18 years old, who signed the informed consent, who underwent follow-up post transplant clinic at the Hospital do Rim for 3 months, receiving immunosuppressive drugs tacrolimus, prednisone and sodium mycophenolate or tacrolimus, azathioprine, and prednisone. Exclusion criteria were patients who underwent second kidney transplant, which did not follow the Hospital do Rim after transplant and who were participating in some other study with pharmaceutical intervention.
Randomization The randomization plan was carried out in blocks and stratified by immunosuppressive drugs tacrolimus, prednisone and mycophenolate sodium or tacrolimus, prednisone and azathioprine.
Opaque envelopes were made from a table of random numbers and they were open on the day of randomization to determine the group to which each patient was allocated group 1 with pharmaceutical intervention or group 2 without pharmaceutical intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients who underwent renal transplantation aged ≥18 years old,
- who signed the informed consent,
- who underwent follow-up post transplant clinic at the Hospital do Rim for 3 months,
- receiving immunosuppressive drugs tacrolimus, prednisone and sodium mycophenolate or tacrolimus, azathioprine, and prednisone.
Exclusion Criteria:
- were patients who underwent second kidney transplant,
- which did not follow the Hospital do Rim after transplant and who were participating in some other study with pharmaceutical intervention.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 with pharmaceutical intervention
Patients allocated to group 1 with pharmaceutical intervention received instructions on the proper use of immunosuppressants as dosage, frequency and administration schedules, importance of immunosuppressive drugs and the risk of rejection. No more interventions were applied. |
Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant.
Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration.
In addition to these guidelines, pharmacists helped patients in filling out the patient diary.
This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them.
This was a standardized pharmacist intervention.
|
No Intervention: 2 without pharmaceutical intervention
Standard following of the Hospital do Rim, without pharmaceutical intervention. This group was just followed by the nurses of the hospital, but without a standardized intervention. It was not a intervention, it was the control group |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary end-point was the influence of pharmaceutical intervention in tacrolimus intra-subject variability during the first 3 months after kidney transplant. variability during the first 3 months after transplantation.
Time Frame: 3 months
|
Coefficients of variation were calculated from the average of dose-corrected tacrolimus blood concentration(CV= SD x 100/mean) of study visits day 10, 14, 21, 30, 60 and 90 post kidney transplant.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess patient adherence through validated questionnaire "Portuguese version of BAASIS scale (Basel Scale Adherence Rating Immunosuppressive Drugs)";
Time Frame: 3 months
|
It consists of a four-item questionnaire measuring nonadherence to immunosuppressives over the past four weeks.
This questionnaire assesses omission of single doses or successive doses, timing deviations >2h and dose reductions.
Responses are given on a six-point scale: never, once per month, every second week, every week, more than once per week and every day.
Patients that answer different from "never" in any of the four questions are considered as nonadherent.
|
3 months
|
Secondary outcomes included evaluate percentage of patients who achieved target levels of tacrolimus in day study visits day 7, 10, 14, 21, 28, 60 e 90 post kidney transplant
Time Frame: 3 months
|
3 months
|
|
We also evaluated renal function (eGFR by MDRD formula)
Time Frame: 3 months
|
3 months
|
|
Tacrolimus bioavailability profile during the period of 3 months
Time Frame: 3 months
|
Characterized by mean and standard deviation of dose corrected tacrolimus blood concentrations(ng/ml/mg)
|
3 months
|
We evaluated the incidence of Infections
Time Frame: 3 months
|
3 months
|
|
We evaluated treated acute rejection episodes
Time Frame: 3 months
|
3 months
|
|
We evaluated death cases
Time Frame: 3 months
|
3 months
|
|
We evaluated graft loss cases
Time Frame: 3 months
|
3 months
|
|
We evaluated discontinuation of immunosuppressive treatment
Time Frame: 3 months
|
3 months
|
|
We evaluated hospital readmissions.
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Adrieli BA Bessa, Pharmacist, Hospital do Rim
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Hospital do Rim
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplant Graft Failure
-
University of EdinburghKidney Cancer UKTerminatedRenal Transplant Rejection | Renal Transplant FailureUnited Kingdom
-
Loma Linda UniversityRecruitingGraft Failure | Acute Rejection of Renal TransplantUnited States
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
PfizerCompletedRenal Transplant | Graft Rejection | Kidney Transplant | Renal Allograft RecipientsUnited States, Australia, Germany, Italy, Spain, Brazil, Argentina
-
Peking University People's HospitalUnknown
-
Baylor Research InstituteActive, not recruitingCompliance, Patient | Graft Failure | Heart Transplant RejectionUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedGraft Rejection | Kidney Failure | Kidney Transplant
-
Universitaire Ziekenhuizen KU LeuvenCompletedAcute Rejection of Renal Transplant | Renal Graft LossBelgium
-
Yale UniversityJohns Hopkins University; National Institute of Diabetes and Digestive and...CompletedEnd Stage Renal Disease | Acute Kidney Injury | Graft Failure | Delayed Graft Function | Deceased Donor Kidney TransplantUnited States
-
University of PisaRecruitingGraft Vs Host Disease | Stem Cell Transplant Complications | Transplant FailureItaly
Clinical Trials on Pharmaceutical Intervention
-
Hospital de Clinicas de Porto AlegreRecruiting
-
Federal University of BahiaCompleted
-
University Hospital, GhentGlaxoSmithKline; University GhentCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium
-
Federal University of BahiaCompletedPharmaceutical Care | Systemic Arterial Hypertension | PharmacotherapyBrazil
-
University Hospital, MontpellierCompletedOrthopaedic Surgery | TraumatologyFrance
-
Universitaire Ziekenhuizen KU LeuvenCompletedHeart FailureBelgium
-
Florida State UniversityBoston University; Children's Hospital of Philadelphia; University of Miami; Boston... and other collaboratorsCompletedAutism Spectrum DisorderUnited States
-
Alcon ResearchJohns Hopkins University; University of PennsylvaniaCompleted
-
Albert Einstein Healthcare NetworkMerck Sharp & Dohme LLCRecruiting
-
Rabin Medical CenterCompletedHip Fractures | Rehabilitation Outcome | Clinical PharmacistsIsrael